Navigation Links
A New Zealand Experience That Improves Lives: Arizona Man Finds Affordable, Quality Healthcare and Freedom From Constant Hip Pain on Recent Trip
Date:4/8/2009

Medtral New Zealand offers complete medical travel packages for North American patients seeking a viable, safe alternative to expensive healthcare treatment.

Long Beach, CA (PRWEB) April 8, 2009 -- Bob Light reached a painful crossroads in his life. The Phoenix, Arizona man was in dire need of a new hip replacement, but couldn't afford the surgery as he has no health insurance. At the same time, Light worried about putting off treatment as the hip pain that bothered him much of his adult life was worsening by the day.

As one of the more than 750,000 Americans who have traveled for medical treatment by the end of last year, Light looked abroad for an alternative to his healthcare dilemma. Late last year he decided to explore an intriguing medical travel opportunity in New Zealand following a timely suggestion from a business associate.

Medtral New Zealand provided a complete medical travel package for Light - including airfare, hospital stay, treatment, staff, accommodations after treatment and a contingency insurance policy - at a fraction of what it would have cost him in the U.S.

Medtral New Zealand offers top-notch medical care and world-class non-acute surgical treatment in an English speaking, first world country. The hospitals employed by Medtral are all accredited by Quality Health New Zealand (QHNZ) and adhere to stringent quality standards. QHNZ is in fact accredited by the international organization International Society for Quality in Healthcare (ISQua), which is responsible for setting the healthcare standards of the Joint Commission International (JCI) accreditation system used in the U.S.

Interest in
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Canadian, German, Israeli, New Zealand, U.K and U.S. Companies Selected to Make Company Presentations at AdvaMed 2008
2. New Zealand Waynes New Resources Development Co., Ltd. Completes Reverse Merger to Go Public in the U.S.
3. Abbott Nutrition Announces Voluntary Recall of ZonePerfect(R) Chocolate Peanut Butter Bars, ZonePerfect(R) Peanut Toffee Bars and NutriPals(TM) Peanut Butter Chocolate Bars in U.S., Mexico, New Zealand and Singapore
4. Fonterras New ClearProtein(TM) Satiety Water a First for New Zealand Market
5. Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers
6. UK junior doctors gaining less experience of common procedures
7. Experiments Get Close to Out-of-Body Experience
8. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
9. National Movement Disorders Interactive Experience Center Comes to Tampa Bay for First Time
10. J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas
11. Guardians Dental Network Experiences Double-Digit Growth
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A New Zealand Experience That Improves Lives: Arizona Man Finds Affordable, Quality Healthcare and Freedom From Constant Hip Pain on Recent Trip
A New Zealand Experience That Improves Lives: Arizona Man Finds Affordable, Quality Healthcare and Freedom From Constant Hip Pain on Recent Trip
Breaking Medicine Technology:Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Daniel K. Spiegelman Elected to Board of Directors of Omeros 2Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2Finally a Health Care Option for Small Businesses 50925 1Finally a Health Care Option for Small Businesses 50925 22009 3A Immunotec announces important clinical research initiative 3A New study to be launched with the goal of improving the quality of the aging pro 12920 12009 3A Immunotec announces important clinical research initiative 3A New study to be launched with the goal of improving the quality of the aging pro 12920 22009 3A Immunotec announces important clinical research initiative 3A New study to be launched with the goal of improving the quality of the aging pro 12920 3Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 1Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 2Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 3Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 4
Other Medicine Technology:Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 2Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 3Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 4Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 5Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 6Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 2Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 3Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 4Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 5Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 6Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 7Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 8Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 9Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 10